Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma

Stopped early

Conditions studied: Melanoma (Skin)

In brief

RATIONALE: Studying the genes expressed in samples of tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at tumor tissue samples from patients with stage I, stage II, or stage III malignant melanoma.

Key facts

Study ID

NCT00991991

Run by

Case Comprehensive Cancer Center

People needed

5

Starts

2009-07-01

Expected to finish

2016-03-01

Last updated by the study team

2016-05-17

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Node positive Group (experimental group)
• Primary melanoma > 2 mm in depth
• Metastasis must be > 0.1 mm and detectable by IHC or hematoxylin and eosin (H\&E) to be considered node positive
• Slides and block for primary and node must be archived in UH dermatopathology
• Node Negative Group (control group)
• Primary melanoma > 2 mm in depth
• A negative sentinel lymph node must be negative by IHC and H\&E
• No stage IV disease
• No acral and mucosal histology
• No history of prior invasive melanoma
• Underwent primary excision and sentinel lymph node biopsy within 3 months of each other
• Archived tissue available
• Slides and block for primary tumor and node biopsy must be archived in University Hospitals Case Medical Center (UH) dermatopathology

You may not qualify if…

• Acral and mucosal histology
• Previous diagnosis of invasive melanoma
• previous chemotherapy or immunotherapy
• patients who are found to have stage IV disease during workup

Where it is running

• Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.